Cutis Laxa Cell Models for Research

Cutis laxa (CL) is a rare heterogeneous connective tissue disorder characterized by loose, sagging, and inelastic skin, with systemic involvement including pulmonary emphysema, cardiovascular anomalies, and gastrointestinal diverticula. The exact prevalence is unknown, but estimates range from 1 in 1,000,000 to 1 in 2,000,000 live births (Orphanet). Both autosomal dominant (AD), autosomal recessive (AR), X-linked, and acquired forms exist. The AR forms often present in infancy with severe systemic complications and high mortality; for example, patients with ATP6V0A2-related cutis laxa (ARCL2A) may have developmental delay and seizures. Mortality is primarily due to pulmonary emphysema, heart failure, or aortic rupture. No specific cure exists; management is supportive. The 5-year survival for severe AR forms can be less than 50% (based on case series). Key risk factors include consanguinity (for AR forms) and family history. The disease burden is significant due to chronic morbidity, need for multidisciplinary care, and limited treatment options.

Cutis laxa serves as a paradigm for understanding elastic fiber biology, extracellular matrix (ECM) homeostasis, and connective tissue disorders. It is ideal for mechanistic studies because:

• • It encompasses defects in multiple genes (ELN, FBLN5, FBLN4, ATP6V0A2, ATP6V1A, PYCR1, LTBP4, etc.) that converge on elastic fiber formation and maintenance.
• • Public datasets (ClinVar, NCBI Gene, UniProt) provide comprehensive mutation and protein information.
• • Open questions include: how do mutations in different genes lead to similar phenotypes? What are the molecular mechanisms of dominant-negative vs. haploinsufficiency effects? How can we target the remaining elastic fiber synthesis for therapy?
• • The disease offers a platform for drug discovery aimed at enhancing elastogenesis, reducing inflammation, and preventing aneurysm formation.

Cutis laxa is not a cancer, but its molecular pathways overlap with those involved in ECM remodeling and TGF-beta signaling, which are also relevant in cancer. The major pathways include:

1. Elastic Fiber Assembly Pathway:

• • Elastin (ELN) is the core component; mutations cause haploinsufficiency (AD) or absent protein (AR).
• • Fibrillin-4 (FBLN4) and Fibrillin-5 (FBLN5) are essential for elastogenesis; mutations impair microfibril formation.
• • Lysyl oxidase (LOX) crosslinks elastin; its activity can be affected indirectly.

2. TGF-beta Signaling Pathway:

• • LTBP4 mutations disrupt latent TGF-beta binding protein 4, leading to altered TGF-beta bioavailability.
• • Increased TGF-beta signaling contributes to vascular pathology and fibrosis.

3. Metabolic and Mitochondrial Pathways:

• • ATP6V0A2 and ATP6V1A mutations affect vacuolar H+-ATPase, leading to impaired glycosylation and mitochondrial dysfunction.
• • PYCR1 mutations affect proline synthesis, impacting collagen and elastin production.

4. Autophagy and Cellular Senescence:

• • Defective autophagy and increased senescence are observed in fibroblasts from CL patients, contributing to ECM degradation.

The following table summarizes the major genes implicated in cutis laxa, their mutation frequencies (based on ClinVar and literature), mutation types, and functional effects.

Note: Frequencies are approximate and vary by population. Data from ClinVar, COSMIC (for somatic mutations in related pathways), and literature.

Key signaling networks deregulated in cutis laxa include:

• • TGF-beta Signaling:
• • LTBP4 mutations lead to decreased latent TGF-beta sequestration, increasing active TGF-beta.
• • SMAD2/3 phosphorylation is enhanced, promoting fibrosis and vascular remodeling.
• • Elastic Fiber Assembly Network:
• • ELN, FBLN4, FBLN5, and LOX interact to form elastic fibers.
• • Mutations disrupt microfibril formation and crosslinking.
• • Glycosylation and Vesicular Trafficking:
• • ATP6V0A2 and ATP6V1A mutations impair Golgi glycosylation, affecting ECM protein secretion.
• • Mitochondrial Function and Oxidative Stress:
• • PYCR1 and ATP6V0A2 mutations lead to increased reactive oxygen species (ROS) and reduced ATP production.
• • Autophagy-Lysosomal Pathway:
• • Impaired autophagy leads to accumulation of damaged proteins and organelles, contributing to cellular senescence.

Several cell lines and organoid models are used to study cutis laxa. The table below lists common cell lines, their origin, and key mutations.

Organoid advantages: Patient-derived skin organoids and vascular organoids can model elastic fiber formation in 3D, providing more physiologically relevant systems for drug testing. They allow study of cell-matrix interactions and can be gene-edited using CRISPR.

Note: Many patient-derived fibroblasts are available from commercial repositories (e.g., Coriell).

Animal models for cutis laxa include:

• • Genetically Engineered Mouse Models (GEMMs):
• • Eln knockout mice: die shortly after birth due to aortic obstruction; heterozygous mice show reduced elastin and hypertension.
• • Fbln5 knockout mice: develop loose skin, emphysema, and aortic aneurysms.
• • Atp6v0a2 knockout mice: exhibit impaired glycosylation and skin laxity.
• • Pycr1 knockout mice: show mitochondrial dysfunction and skin aging.
• • Induced Models:
• • Elastase-induced emphysema models in mice to mimic pulmonary involvement.
• • Beta-aminopropionitrile (BAPN) treatment to inhibit lysyl oxidase, causing elastic fiber defects.
• • Patient-Derived Xenografts (PDX):
• • Fibroblasts from CL patients injected into immunodeficient mice to study ECM remodeling.

These models are valuable for preclinical testing of drugs targeting elastogenesis and TGF-beta signaling.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with specific mutations in cutis laxa genes. Examples include:

• • ELN knockout in human dermal fibroblasts to model ADCL haploinsufficiency.
• • FBLN5 knockout in HEK293T cells to study elastogenesis.
• • ATP6V0A2 knockout in HeLa cells to investigate glycosylation defects.
• • Knock-in of patient-specific mutations (e.g., ELN p.Gly610Val) to study dominant-negative effects.
• • Reporter lines: ELN promoter-driven GFP reporter in fibroblasts to screen for compounds that enhance elastin expression.

Commercially available, sequence-verified gene-edited cell models can accelerate research by providing consistent and reproducible tools. These models are engineered using CRISPR and validated by Sanger sequencing and functional assays. They enable researchers to study disease mechanisms and test potential therapeutics without the variability of patient-derived cells.

Gene-edited cell models are crucial for functional genomics in cutis laxa:

• • Knockout of ELN in fibroblasts confirms its role in elastic fiber formation and allows identification of compensatory pathways.
• • Knock-in of specific mutations (e.g., FBLN5 p.Ser227Pro) helps determine whether they are loss-of-function or dominant-negative.
• • CRISPR screens can identify modifier genes that exacerbate or ameliorate the phenotype.
• • Examples: A study using ELN knockout fibroblasts showed upregulation of TGF-beta signaling, suggesting a feedback loop.

These models validate gene function and provide insights into disease mechanisms.

Isogenic pairs (wild-type vs. mutant) are ideal for drug screening:

• • High-throughput screening of small molecules that restore elastic fiber formation in ELN or FBLN5 knockout cells.
• • Testing of TGF-beta inhibitors (e.g., losartan) in ATP6V0A2 knockout cells to reduce fibrosis.
• • Resistance modeling: Cancer drugs that target ECM (e.g., lysyl oxidase inhibitors) can be tested for efficacy and resistance in CL models.
• • Gene-edited cells provide a consistent platform for measuring drug response and identifying biomarkers of resistance.

CRISPR synthetic lethality screens in cutis laxa models can uncover novel therapeutic targets:

• • Genome-wide knockout screens in ELN-mutant cells to identify genes whose loss is lethal only in the mutant background.
• • Identification of biomarkers for disease severity, such as elevated TGF-beta levels or specific microRNAs.
• • Use of reporter lines to monitor elastin expression and identify compounds that upregulate it.
• • These approaches can lead to precision medicine strategies for cutis laxa patients.